Trial reportEuropean journal of applied physiology2026
Effect of sodium bicarbonate on performance and markers of kidney and gastrointestinal injury during repeated sprints in the heat.
Trial report in European journal of applied physiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
purposeWe tested the hypotheses that sodium bicarbonate (SB) supplementation improves performance, reduces markers of acute kidney injury (AKI) risk, and increases markers of acute gastrointestinal injury (AGI) during repeated sprints in the heat.
methodsUsing a double-blind design, 10 recreationally endurance-trained participants ingested 0.2 g/kg of body weight of SB or placebo before cycling in the heat (dry-bulb: 40 °C, relative humidity: 20%). Exercise bouts included a 22-min warm-up, then 4-sets of 5 × 6-sec maximal-effort standing cycling sprints. Core temperature (Tc) was measured at baseline, end of warm-up, after set two of sprints, and post-exercise bouts. Urine and plasma collected pre-ingestion and pre-, post-, and 1-h post-exercise were analyzed for markers of AKI risk, AGI, and endotoxemia.
resultsSB increased peak (average difference between conditions: 21 ± 11 W, condition effect: p = 0.02) and average (p = 0.03) power across the sprints. Tc increased from pre- to post-exercise (placebo: Δ1.3 ± 0.3 °C, SB: Δ1.4 ± 0.4 °C, time effect: p < 0.001), but there were no effects of condition or interaction. Exercise increased the primary marker of AKI (urinary IGFBP7×TIMP-2, time effect: p = 0.005) but not urinary NGAL. There were no condition or interaction effects for either AKI marker. Plasma I-FABP, a marker of AGI, increased post-exercise bouts (placebo: Δ291 ± 550 pg/mL, SB: Δ397 ± 482 pg/mL, p = 0.03), with no condition or interaction effects. There were no significant effects for markers of endotoxemia (LBP, sCD14).
conclusionsSB supplementation improves repeat sprint performance in the heat without altering Tc, markers of AKI risk, or markers of AGI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.